In a significant stride toward transforming the landscape of oncological care, IceCure Medical has officially commenced patient enrollment for its pivotal ChoICE study. This prospective, post-marketing clinical trial is designed to evaluate the real-world performance of the ProSense cryoablation system, a breakthrough technology that offers a minimally invasive alternative to traditional surgical excision for patients diagnosed with low-risk breast cancer.
The initiation of the study marks a critical milestone for IceCure Medical as it seeks to solidify the clinical standing of its cryoablation platform within the United States. By gathering robust, real-world evidence, the company aims to demonstrate that its freezing-based technology can be as effective—and far less traumatic—than conventional surgical interventions.
Main Facts: The ChoICE Study Framework
The ChoICE study is an ambitious clinical initiative that seeks to recruit approximately 400 participants across a geographically diverse network of up to 30 specialized medical centers in the United States. The primary objective is to provide comprehensive data on the efficacy, safety, and patient experience associated with the ProSense system when used within its FDA-cleared indications.
ProSense currently holds the distinction of being the only medical device approved by the US Food and Drug Administration (FDA) for the local treatment of biologically low-risk breast tumors. Specifically, the device is indicated for tumors measuring 1.5cm or smaller in patients aged 70 and older who are also receiving adjuvant endocrine therapy, or those who are deemed medically ineligible for traditional surgery.
A unique feature of this clinical program is the dual-role designation of participating facilities. These centers operate as both clinical trial sites and commercial providers. This structure allows medical teams to integrate the study into their routine clinical practice while simultaneously offering the ProSense procedure to qualifying patients who may not fit the strict criteria of the trial cohort, thereby expanding access to the technology.
Chronology of Clinical Development
The path to the ChoICE study has been defined by rigorous regulatory navigation and strategic site selection. The program gained momentum in August 2026, when several prestigious medical institutions finalized site contracts and secured the necessary institutional review board (IRB) approvals to begin patient recruitment.
The official launch of the study was marked by two landmark patient enrollments:
- West Cancer Center & Research Institute (Germantown, Tennessee): The first patient was successfully enrolled under the guidance of Dr. Richard Fine, the director of the Margaret West Comprehensive Breast Center and the lead author of the earlier, successful ICE3 study. Dr. Fine’s involvement provides continuity, as his previous work on cryoablation for small, low-risk tumors laid the groundwork for this broader, post-market assessment.
- Adventist Health Glendale (California): The second subject was enrolled shortly thereafter, led by esteemed breast surgeon Dr. Dennis Holmes.
Following these initial successes, IceCure has continued to aggressively expand its footprint. The company recently integrated Legacy Health’s Legacy Medical Group—Surgical Oncology at the Good Samaritan Medical Center in Portland, Oregon—into the trial network, signaling a rapid acceleration in the study’s operational capabilities.
Supporting Data: The Science of Cryoablation
At the heart of the ChoICE study is the ProSense system’s unique mechanism of action. Unlike traditional surgery, which requires the physical removal of tissue, ProSense utilizes extreme cold to eradicate tumors. The system inserts a thin, probe-like device into the breast, where it circulates liquid nitrogen to create an "ice ball" that encompasses the tumor. This process destroys cancerous cells while leaving surrounding healthy tissue largely unaffected.
The clinical argument for cryoablation is compelling. Traditional lumpectomies or mastectomies, while effective, involve significant recovery times, the risks of anesthesia, potential scarring, and the psychological burden of surgical removal. Cryoablation can often be performed in an outpatient setting under local anesthesia, significantly reducing the "surgical footprint" on the patient.
The data gathered in the ChoICE study will supplement the findings of the ICE3 study, which served as the cornerstone for the FDA’s initial clearance. By moving into a post-marketing, real-world setting, IceCure hopes to provide stakeholders, oncologists, and patients with long-term survival and quality-of-life data that mirrors the outcomes of clinical trials in a day-to-day hospital environment.
Official Responses and Strategic Vision
Eyal Shamir, CEO of IceCure Medical, highlighted the strategic importance of this rollout in a recent statement. "Enrolling the first patients marks continued progress in the execution of our post-market strategy for ProSense," Shamir remarked. "As we continue to expand the ChoICE Study’s clinical network, we aim to generate additional real-world evidence while supporting broader clinical adoption and access to minimally invasive cryoablation for eligible patients."
The company’s leadership views the ChoICE study not merely as a regulatory requirement, but as an engine for market penetration. By demonstrating the efficacy of ProSense in diverse real-world settings, IceCure is building the evidence base required to persuade healthcare payers and hospital systems to adopt cryoablation as a standard-of-care option.
IceCure’s expansion strategy is global in scope. Beyond the US trial, the company maintains a strong international presence, with the ProSense system marketed across Europe and Asia. In a move to further solidify its European operations, the company signed an exclusive distribution agreement with Scovas Medical in August 2026, specifically targeting the Dutch market.
Implications for the Future of Oncology
The implications of the ChoICE study extend far beyond the immediate goal of gathering data. If the study successfully confirms that ProSense delivers consistent, reliable results in real-world clinical practice, it could trigger a paradigm shift in how early-stage breast cancer is managed.
1. Shift Toward "Office-Based" Oncology
The success of ProSense could decentralize breast cancer treatment. By moving the procedure from the surgical theater to the outpatient clinic, hospitals can optimize their resource allocation, and patients can experience a more streamlined, less invasive journey to recovery.
2. Broadening Patient Eligibility
Currently, the FDA indication for ProSense is relatively narrow, focusing on patients aged 70 and older or those unfit for surgery. However, should the ChoICE study yield strong safety and efficacy data, it may provide the clinical impetus for the FDA to consider expanding the labeling to include a younger demographic or different types of breast lesions, effectively widening the addressable market for cryoablation.
3. Economic Impact
From a health economics perspective, cryoablation represents a potentially cost-effective alternative to surgery. By eliminating the need for general anesthesia and reducing hospital stays, the procedure may lower the overall cost of care for healthcare providers and insurers. The data from the ChoICE study will be instrumental in developing these health-economic arguments.
4. Patient Quality of Life
Perhaps most importantly, the psychological impact of avoiding invasive surgery cannot be overstated. For patients, the ability to address a tumor without the aesthetic and physical trauma of traditional surgery represents a major advancement in patient-centered care.
Conclusion
As the ChoICE study gains momentum across the United States, the medical community is watching closely. By balancing clinical rigor with the realities of modern medical practice, IceCure Medical is positioning itself at the forefront of a technological revolution in breast cancer treatment. With the enrollment of the first participants, the industry is one step closer to proving that the most effective way to treat some of the most challenging conditions may not be to cut, but to freeze. As the trial progresses toward its goal of 400 participants, the evidence gathered will likely serve as a blueprint for the next decade of minimally invasive oncological intervention.
About the Author
